Inventor
ALTINTAS ISIL
NL17 patents
⚠️ This page may combine multiple inventors who share the name “ALTINTAS ISIL”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GENMAB AS
12 patentsUS11440966B2Sep 13, 2022
Multispecific antibodies against CD40 and CD137
GENMAB AS12 citations94
US10544220B2Jan 28, 2020
Bispecific antibodies against CD3 and CD20
GENMAB AS18 citations93
US10407501B2Sep 10, 2019
Humanized or chimeric CD3 antibodies
GENMAB AS15 citations93
US11091557B2Aug 17, 2021
Methods of producing multispecific antibodies against CD40 and CD137
GENMAB AS10 citations85
US11084882B2Aug 10, 2021
Multispecific antibodies against CD40 and CD137
GENMAB AS8 citations84
US11613575B2Mar 28, 2023
Humanized or chimeric CD3 antibodies
GENMAB AS4 citations74
US11359015B2Jun 14, 2022
Humanized or chimeric CD3 antibodies
GENMAB AS6 citations74
US12077596B2Sep 3, 2024
Multispecific antibodies against CD40 and CD137
GENMAB AS2 citations73
US11939388B2Mar 26, 2024
Multispecific antibodies against CD40 and CD137
GENMAB AS2 citations73
US11459395B2Oct 4, 2022
Binding agents binding to PD-L1 and CD137 and use thereof
GENMAB AS1 citations71
US12570751B2Mar 10, 2026
Binding agents binding to PD-L1 and CD137 and use thereof
GENMAB AS0 citations61
US10968280B2Apr 6, 2021
Binding agents binding to PD-L1 and CD137 and use thereof
GENMAB AS1 citations61
BioNTech SE
3 patentsUS12421319B2Sep 23, 2025
Binding agents that bind OX40 (CD134) and method of use thereof to treat disease
BioNTech SE0 citations62
US11814411B2Nov 14, 2023
Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)
BioNTech SE0 citations62
US10927181B2Feb 23, 2021
Agonistic tumor necrosis factor (TNF) receptor binding agents
BioNTech SE0 citations62